Reviva Pharmaceuticals Reports Decreased Net Loss and Increased Assets in Latest 10-Q Filing

Reviva Pharmaceuticals Holdings, Inc. reported significant financial developments in its latest 10-Q filing for the quarter ending June 30, 2026. The company recorded a net loss of $2.4 million for the three months ended June 30, 2026, a notable decrease from the $6.1 million loss reported in the same period of the previous year. For the first half of 2026, the net loss was approximately $5.6 million, down from $12.5 million in the first half of 2025. The reduction in losses is attributed to a decrease in operating expenses, which fell to $2.6 million in Q2 2026 from $6.1 million in Q2 2025, primarily due to lower research and development costs.

The company’s total assets increased to $21.1 million as of June 30, 2026, compared to $15.9 million at the end of 2025. This growth was driven by a rise in cash and cash equivalents, which reached $19.9 million, up from $14.4 million at the end of the previous fiscal year. Reviva's total liabilities also decreased significantly, from $7.3 million at the end of 2025 to $5.9 million by mid-2026, reflecting a reduction in short-term debt and accounts payable.

Strategically, Reviva has made notable moves, including a public offering completed in March 2026, which raised approximately $10 million in gross proceeds. This offering included the sale of 6.3 million shares of common stock and warrants. The company also executed a reverse stock split in March 2026, consolidating its shares to comply with Nasdaq listing requirements, although it was subsequently delisted from Nasdaq and is now quoted on the OTCQB Venture Market. The company’s stock count increased to 13.1 million shares outstanding as of June 30, 2026, compared to 5.9 million shares at the end of 2025.

Operationally, Reviva has focused on its clinical development efforts, particularly in the central nervous system and cardiometabolic disease sectors. The company reported a working capital surplus of approximately $15.2 million, which it believes will support its operations into mid-2027. However, Reviva cautioned that it will require additional funding to sustain its development activities and operations beyond this period. The company plans to pursue further fundraising through equity or debt financing, although it acknowledged the uncertainty surrounding the availability of such funding.

Looking ahead, Reviva anticipates continued operating losses as it invests in research and development to advance its product candidates. The company emphasized the need to generate significant revenues to achieve profitability, which remains uncertain. The management's outlook reflects a cautious approach, recognizing the challenges of the clinical-stage pharmaceutical landscape and the necessity for ongoing financial support to meet its operational goals.